Valuation: Candel Therapeutics, Inc.

Market Cap 766M 665M 623M 570M 1.08B 73.01B 1.09B 7.29B 2.86B 36.48B 2.88B 2.82B 121B P/E 2026 *
-11.6x
P/E 2027 * -14.7x
Enterprise Value 766M 665M 623M 570M 1.08B 73.01B 1.09B 7.29B 2.86B 36.48B 2.88B 2.82B 121B EV / Sales 2026 *
-
EV / Sales 2027 * 17.9x
Free-Float
84.33%
Yield 2026 *
-
Yield 2027 * -
07-13 Stifel Nicolaus Initiates Coverage on Candel Therapeutics With Buy Rating, $22 Price Target MT
06-30 Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-Cancer Drug DJ
06-30 Candel Therapeutics, Inc. Initiates Global Pivotal Phase 3 Aurora Trial Evaluating Aglatimagene Besadenovec In Advanced Non-Small Cell Lung Cancer Patients With Inadequate Response To Immune Checkpoint Inhibitors CI
06-25 Candel Therapeutics, Inc. Appoints Mark Sims as Chief Commercial Officer, Effective July 6, 2026 CI
06-22 Candel Therapeutics, Inc.(NasdaqGM:CADL) added to S&P Biotechnology Select Industry Index CI
06-02 Candel Therapeutics, Inc. Announces Publication in the Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (Can-2409) in Localized Prostate Cancer CI
05-21 Certain Warrants of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI
05-21 Certain Stock Options of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI
05-21 54,895,849 Common Stock of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI
05-15 Candel Therapeutics reports extended clinical benefit over multiple clinical endpoints in patients from phase 3 trial of aglatimagene besadenovec (CAN-2409) RE
05-15 Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (CAN-2409) In Localized Prostate Cancer Under Prolonged Follow-Up At AUA 2026 Annual Meeting CI
05-15 Candel Therapeutics, Inc. - Special Call
05-14 Candel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI

Last Transcript: Candel Therapeutics, Inc.

1 day+1.15%
1 week+7.19%
Current month+5.69%
1 month+5.48%
3 months+38.66%
6 months+81.48%
Current year+87.26%
1 week 9.51
Extreme 9.51
10.82
1 month 9.16
Extreme 9.1612
10.82
Current year 4.44
Extreme 4.44
11.36
1 year 4.35
Extreme 4.35
11.36
3 years 0.66
Extreme 0.66
14.6
5 years 0.66
Extreme 0.66
14.78
10 years 0.66
Extreme 0.66
14.78
Manager TitleAgeSince
Chief Executive Officer 66 01/09/2020
Director of Finance/CFO 41 12/01/2024
Chief Tech/Sci/R&D Officer 57 12/09/2022
Director TitleAgeSince
Director/Board Member 80 01/09/2017
Director/Board Member 66 01/09/2020
Chairman 70 15/07/2021
Date Insider Type Main position Quantity % Market Cap.
7/6/26 A Free

Executive/Senior Manager

285,000 0.3890%
6/30/26 A Free

Director

381 0.0005%
6/30/26 A Free

Director

1,331 0.0018%
Change 5-day change 1-year change 3-year change Capi.($)
+1.15%+7.19%+77.52%+888.79% 766M
+0.93%-1.43%+1.61%+14.93% 48.57B
+0.26%+2.93%+439.43%+567.38% 41.95B
-1.53%-2.25%+30.95%+5.99% 38.85B
+0.69%+2.40%+10.48%+75.87% 37.24B
+2.47%+8.33%+15.16%+48.37% 30.67B
-0.47%+1.16%+35.93%+124.67% 16.41B
+2.31%-0.49% - - 16.1B
+0.29%+1.81%+4.92%+18.60% 13.97B
-1.43%-2.63%+3.70%-35.93% 12.62B
Average +0.27%+0.86%+68.86%+189.85% 25.71B
Weighted average by Cap. +0.31%+0.43%+88.51%+131.10%

Financials

2026 *2027 *
Net sales - 42.84M 37.17M 34.81M 31.84M 60.11M 4.08B 60.89M 407M 160M 2.04B 161M 157M 6.79B
Net income -61.55M -53.41M -50.01M -45.75M -86.37M -5.86B -87.49M -585M -230M -2.93B -231M -226M -9.75B -54.13M -46.97M -43.98M -40.23M -75.95M -5.16B -76.94M -515M -202M -2.58B -203M -199M -8.57B
Net Debt - -
Logo Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Employees
55
Date Price Change Volume
06/08/26 $10.58 +1.15% 1,295,845
05/08/26 $10.46 -0.48% 750,662
04/08/26 $10.51 +4.37% 1,072,773
03/08/26 $10.07 +0.60% 879,390
31/07/26 $10.01 +1.42% 1,117,505
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
10.46USD
Average target price
20.50USD
Spread / Average Target
+95.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CADL Stock